The Relation of VEGFA, VEGFR2, VEGI, and HIF1A Genetic Variants and Their Serum Protein Levels with Breast Cancer in Egyptian Patients

Overview

Journal Biochem Genet

Specialty Molecular Biology

Date 2023 Jul 1

PMID 37392242

Authors

Amani A Abdelgalil

Rehan Monir

Mohamed Elmetwally

Maivel H Ghattas

Fagr B Bazeed

Noha M Mesbah

Dina M Abo-Elmatty

Eman T Mehanna

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common type of cancer in Egyptian females. Polymorphisms in the angiogenesis pathway have been implicated previously in cancer risk and prognosis. The aim of the current study was to determine whether certain polymorphisms in the genes of vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor receptor 2 (VEGFR2), vascular endothelial growth inhibitor (VEGI), and hypoxia-inducible factor-1α (HIF1A) associated with breast cancer development. The study included 154 breast cancer patients and 132 apparently healthy age-matched females as a control group. VEGFA rs25648 genotyping was performed using (ARMS) PCR technique; while VEGFR2 rs2071559, VEGI rs6478106, and HIF-1α rs11549465 were genotyped by the PCR-RFLP method. Serum levels of VEGF, VEGFR2, VEGI, and HIF1A proteins in breast cancer patients and controls were measured by ELISA. There was a significant association between the VEGFA rs25648 C allele and breast cancer risk (OR 2.5, 95% CI 1.7-3.6, p < 0.001). VEGFA rs25648 C/C genotype was statistically significantly higher in breast cancer patients vs. control (p < 0.001). Participants with the T/T and T/C VEGFR2 rs2071559 genotypes had 5.46 and 5 higher odds, respectively, of having breast cancer than those with the C/C genotype. For the VEGI rs6478106 polymorphism, there was a higher proportion of C allele in breast cancer patients vs. control (p = 0.003). Moreover, the C/C genotype of VEGI rs6478106 was statistically significantly higher in breast cancer patients vs. control (p = 0.001). There was no significant difference in genotypes and allele frequencies of HIF1A rs11549465 polymorphism between breast cancer cases and control individuals (p > 0.05). Serum levels of VEGFA, VEGI, and HIF1A were considerably greater in women with breast cancer than in the control (p < 0.001). In conclusion, the genetic variants VEGFA rs25648, VEGFR2 rs2071559, and VEGI rs6478106 revealed a significant association with increased breast cancer risk in Egyptian patients.

Citing Articles

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) rs2071559 Gene Polymorphism and the Risk of Gliomas: A Systematic Review and Meta-Analysis.

Prasetiyo P, Wahjoepramono E J Clin Med. 2024; 13(15).

PMID: 39124599 PMC: 11313419. DOI: 10.3390/jcm13154332.

References

Albalawi I, Mir R, Abu Duhier F . Genetic Effects of Vascular Endothelial Growth Factor A (VEGF-A) and Its Association with Disease Progression in Breast Cancer Population of Saudi Arabia. Asian Pac J Cancer Prev. 2020; 21(1):139-145. PMC: 7294010. DOI: 10.31557/APJCP.2020.21.1.139. View

Al-Habboubi H, Sater M, Almawi A, Al-Khateeb G, Almawi W . Contribution of VEGF polymorphisms to variation in VEGF serum levels in a healthy population. Eur Cytokine Netw. 2011; 22(3):154-8. DOI: 10.1684/ecn.2011.0289. View

Apaydin I, Konac E, Onen H, Akbaba M, Tekin E, Ekmekci A . Single nucleotide polymorphisms in the hypoxia-inducible factor-1alpha (HIF-1alpha) gene in human sporadic breast cancer. Arch Med Res. 2008; 39(3):338-45. DOI: 10.1016/j.arcmed.2007.11.012. View

Autiero M, Luttun A, Tjwa M, Carmeliet P . Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003; 1(7):1356-70. DOI: 10.1046/j.1538-7836.2003.00263.x. View

Balasubramanian S, Brown N, Reed M . Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer. 2002; 87(10):1057-65. PMC: 2376194. DOI: 10.1038/sj.bjc.6600625. View

Balasubramanian S, Cox A, Cross S, Higham S, Brown N, Reed M . Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer. 2007; 121(5):1009-16. DOI: 10.1002/ijc.22772. View

Bamias G, Siakavellas S, Stamatelopoulos K, Chryssochoou E, Papamichael C, Sfikakis P . Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol. 2008; 129(2):249-55. DOI: 10.1016/j.clim.2008.07.014. View

Bray F, Ren J, Masuyer E, Ferlay J . Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2012; 132(5):1133-45. DOI: 10.1002/ijc.27711. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Carmeliet P . VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69 Suppl 3:4-10. DOI: 10.1159/000088478. View

11.

Chen Y, Dawes P, Mattey D . Polymorphism in the vascular endothelial growth factor A (VEGFA) gene is associated with serum VEGF-A level and disease activity in rheumatoid arthritis: differential effect of cigarette smoking. Cytokine. 2012; 58(3):390-7. DOI: 10.1016/j.cyto.2012.02.018. View

12.

Chew L, Pan H, Yu J, Tian S, Huang W, Zhang J . A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J. 2002; 16(7):742-4. DOI: 10.1096/fj.01-0757fje. View

13.

Meka P, Cingeetham A, Nanchari S, Damineni S, Tipirisetti N, Gorre M . HIF-1α (1772C>T) polymorphism as marker for breast cancer development. Tumour Biol. 2014; 36(5):3215-20. DOI: 10.1007/s13277-014-2949-y. View

14.

Das S, Vasudevan D . Essential factors associated with hepatic angiogenesis. Life Sci. 2007; 81(23-24):1555-64. DOI: 10.1016/j.lfs.2007.09.027. View

15.

de Silva P, Nguyen D, Sauk J, Korzenik J, Yajnik V, Ananthakrishnan A . Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther. 2012; 36(5):459-66. DOI: 10.1111/j.1365-2036.2012.05214.x. View

16.

Fallah A, Sadeghinia A, Kahroba H, Samadi A, Heidari H, Bradaran B . Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. Biomed Pharmacother. 2018; 110:775-785. DOI: 10.1016/j.biopha.2018.12.022. View

17.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

18.

Ferrara N . Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009; 29(6):789-91. DOI: 10.1161/ATVBAHA.108.179663. View

19.

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

20.

Fraga A, Ribeiro R, Coelho A, Vizcaino J, Coutinho H, Lopes J . Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. BMC Urol. 2017; 17(1):12. PMC: 5282787. DOI: 10.1186/s12894-017-0201-y. View